Breast cancer stem cells (BCSCs) is a subpopulation of cancer cells with self-renewal and differentiation capacity, have been suggested to give rise to tumor heterogeneity and biologically aggressive behavior. Accumulating evidence has shown that BCSCs play a fundamental role in tumorigenesis, progression, and recurrence. The development of immunotherapy, primarily represented by programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors, has greatly changed the treatment landscape of multiple malignancies. Recent studies have identified pervasive negative associations between cancer stemness and anticancer immunity. Stemness seems to play a causative role in the formation of cold tumor immune microenvironment (TIME). The multiple functions of long non-coding RNAs (lncRNAs) in regulating stemness and immune responses has been recently highlighted in breast cancer. The review focus on lncRNAs and keys pathways involved in the regulation of BCSCs and TIME. Potential clinical applications using lncRNAs as biomarkers or therapies will be discussed.
乳腺癌干细胞（BCSCs）是具有自我更新和分化能力的癌细胞亚群，被认为是导致肿瘤异质性和生物学侵袭行为的重要原因。越来越多的证据表明，BCSCs在肿瘤发生、进展和复发中发挥关键作用。以程序性细胞死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）抑制剂为代表的免疫疗法的发展，极大地改变了多种恶性肿瘤的治疗格局。近期研究发现，肿瘤干性与抗肿瘤免疫之间存在广泛的负相关关系，干性似乎在冷肿瘤免疫微环境（TIME）的形成中起到因果作用。长链非编码RNA（lncRNAs）在调节乳腺癌干性和免疫反应中的多重功能近期受到广泛关注。本综述聚焦于参与调控BCSCs和TIME的lncRNAs及其关键通路，并将探讨lncRNAs作为生物标志物或治疗靶点的潜在临床应用。
肿瘤(癌症)患者之家